Studies have extensively demonstrated that the down-expression of DACH1 is related to poor prognoses in many tumors, such as BC, prostate cancer, lung cancer, and hepatocellular carcinoma [8, 103, 105, 186–188]. Here, DACH1 is linked to prostate cancer.